↓ Skip to main content

Oncotarget

Management of intracranial melanomas in the era of precision medicine

Overview of attention for article published in Oncotarget, July 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter
4 X users
facebook
1 Facebook page

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
36 Mendeley
Title
Management of intracranial melanomas in the era of precision medicine
Published in
Oncotarget, July 2017
DOI 10.18632/oncotarget.19223
Pubmed ID
Authors

Grace J. Young, Wenya Linda Bi, Winona W. Wu, Tanner M. Johanns, Gavin P. Dunn, Ian F. Dunn

Abstract

Melanoma is the most lethal of skin cancers, in part because of its proclivity for rapid and distant metastasis. It is also potentially the most neurotropic cancer in terms of probability of CNS metastasis from the primary lesion. Despite surgical resection and radiotherapy, prognosis remains guarded for patients with brain metastases. Over the past five years, a new domain of personalized therapy has emerged for advanced melanoma patients with the introduction of BRAF and other MAP kinase pathway inhibitors, immunotherapy, and combinatory therapeutic strategies. By targeting critical cellular signaling pathways and unleashing the adaptive immune response against tumor antigens, a subset of melanoma patients have demonstrated remarkable responses to these treatments. Over time, acquired resistance to these modalities inexorably develops, providing new challenges to overcome. We review the rapidly evolving terrain for intracranial melanoma treatment, address likely and potential mechanisms of resistance, as well as evaluate promising future therapeutic approaches currently under clinical investigation.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 10 28%
Student > Ph. D. Student 5 14%
Researcher 4 11%
Student > Doctoral Student 2 6%
Other 2 6%
Other 1 3%
Unknown 12 33%
Readers by discipline Count As %
Medicine and Dentistry 10 28%
Biochemistry, Genetics and Molecular Biology 3 8%
Nursing and Health Professions 2 6%
Agricultural and Biological Sciences 2 6%
Physics and Astronomy 1 3%
Other 3 8%
Unknown 15 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 July 2021.
All research outputs
#14,360,215
of 22,996,001 outputs
Outputs from Oncotarget
#5,616
of 14,341 outputs
Outputs of similar age
#174,377
of 312,373 outputs
Outputs of similar age from Oncotarget
#370
of 1,071 outputs
Altmetric has tracked 22,996,001 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 14,341 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,373 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,071 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.